Sort   by:  
 Page size 
UnknownRandomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201.
Not available
S-EPMC10198543 | biostudies-literature
UnknownOxidation of archaeal peroxiredoxin involves a hypervalent sulfur intermediate.
Not available
S-EPMC2359787 | biostudies-literature
UnknownAssociation of the expression of 5-FU biomarkers with aging and prognosis in elderly patients with lung cancer treated with S-1 adjuvant chemotherapy: Follow-up results of the Setouchi Lung Cancer Group Study 1201.
Not available
S-EPMC12278714 | biostudies-literature
UnknownCritical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness.
Not available
S-EPMC6520639 | biostudies-literature
UnknownImpact of aberrant methylation of microRNA-9 family members on non-small cell lung cancers.
Not available
S-EPMC3956236 | biostudies-literature
UnknownAcquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Not available
S-EPMC4638008 | biostudies-literature
UnknownAntitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
Not available
S-EPMC5891184 | biostudies-literature
UnknownAntitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
Not available
S-EPMC4724821 | biostudies-literature
UnknownTargeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
Not available
S-EPMC5233972 | biostudies-literature
UnknownTherapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Not available
S-EPMC5980184 | biostudies-literature
Sort   by:  
 Page size